Abstract:

Hypertension is among the non-communicable diseases that complicate pregnancies in women. Diagnosis and control of this condition are important in reducing the risk of maternal and foetal mortality. This study was aimed at determining the prevalence and control of hypertension among pregnant women visiting secondary health care facilities in four Local Government Areas in Lagos (2) and Abuja (Federal Capital Territory) (2), Nigeria. Our findings showed that there was a high prevalence of hypertension in these facilities (50%). Our finding also revealed that the overall level of control was 30.45%, which decreased with time in the course of the management. The control was highest in the first quarter and lowest in the third (last) quarter. The consistent and appropriate use of antihypertensives is important to prevent the complications associated with non-communicable diseases like hypertension during pregnancy. Healthcare providers should therefore advocate early diagnosis and management of hypertension during pregnancy.

References:

[1] WHO Hypertension Available online: https://www.who.int/news-room/fact-sheets/detail/hypertension (accessed on 19 October 2023).

[2] Braunthal, S.; Brateanu, A. Hypertension in Pregnancy: Pathophysiology and Treatment. SAGE Open Med. 2019, 7, doi:10.1177/2050312119843700.

[3] Msughter, A.E. “Pregnancy Induced Hypertension in Kabo Local Government Area of Kano State, Nigeria.” Biomed. J. Sci. Tech. Res. 2021, 39, doi:10.26717/BJSTR.2021.39.006321.

[4] Mammaro, A.; Carrara, S.; Cavaliere, A.; Ermito, S.; Dinatale, A.; Pappalardo, E.M.; Militello, M.; Pedata, R.; Cacciatore, A. Hypertensive Disorders of Pregnancy. J. Prenat. Med. 2009, 3, 1.

[5] Beech, A.; Mangos, G. Management of Hypertension in Pregnancy. Aust. Prescr. 2021, 44, 148, doi:10.18773/AUSTPRESCR.2021.039.

[6] Kintiraki, E.; Papakatsika, S.; Kotronis, G.; Goulis, D.G.; Kotsis, V. Pregnancy-Induced Hypertension. Hormones (Athens). 2015, 14, 211–223, doi:10.14310/HORM.2002.1582.

[7] Hossain, N.; Shaikh, Z.F. Maternal Deaths Due to Indirect Causes: Report from a Tertiary Care of a Developing Country. Obstet. Med. 2022, 15, 176, doi:10.1177/1753495X211037916.

[8] Carey, R.M.; Muntner, P.; Bosworth, H.B.; Whelton, P.K. Prevention and Control of Hypertension: JACC Health Promotion Series. J. Am. Coll. Cardiol. 2018, 72, 1278, doi:10.1016/J.JACC.2018.07.008.

[9] Muti, M.; Tshimanga, M.; Notion, G.T.; Bangure, D.; Chonzi, P. Prevalence of Pregnancy Induced Hypertension and Pregnancy Outcomes among Women Seeking Maternity Services in Harare, Zimbabwe. BMC Cardiovasc. Disord. 2015, 15, 1–8, doi:10.1186/S12872-015-0110-5/TABLES/3.

[10] Ebeigbe, P..; Igberase, G..; Aziken, M.. Hypertensive Disorders in Pregnancy: Experience with 442 Recent Consecutive Cases in Benin City, Nigeria. Niger. Med. J. 2007, 48, doi:10.4314/NMJ.V48I4.50895.

[11] Singh, S.; Ahmed, E.B.; Egondu, S.C.; Ikechukwu, N.E. Hypertensive Disorders in Pregnancy among Pregnant Women in a Nigerian Teaching Hospital. Niger. Med. J. 2014, 55, 384, doi:10.4103/0300-1652.140377.

[12] Bello, N.A.; Zhou, H.; Cheetham, T.C.; Miller, E.; Getahun, D.T.; Fassett, M.J.; Reynolds, K. Prevalence of Hypertension Among Pregnant Women When Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association with Maternal and Fetal Outcomes. JAMA Netw. Open 2021, 4, e213808–e213808, doi:10.1001/JAMANETWORKOPEN.2021.3808.

[13] Tebeu, P.M.; Foumane, P.; Mbu, R.; Fosso, G.; Biyaga, P.T.; Fomulu, J.N. Risk Factors for Hypertensive Disorders in Pregnancy: A Report from the Maroua Regional Hospital, Cameroon. J. Reprod. Infertil. 2011, 12, 227.

[14] Brown, C.M.; Garovic, V.D. Drug Treatment of Hypertension in Pregnancy. Drugs 2014, 74, 283, doi:10.1007/S40265-014-0187-7.

[15] Hoeltzenbein, M.; Beck, E.; Fietz, A.K.; Wernicke, J.; Zinke, S.; Kayser, A.; Padberg, S.; Weber-Schoendorfer, C.; Meister, R.; Schaefer, C. Pregnancy Outcome after First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension 2017, 70, 201–208, doi:10.1161/HYPERTENSIONAHA.117.09110.

[16] Folic, M.M.; Jankovic, S.M.; Varjacic, M.R.; Folic, M.D. Effects of Methyldopa and Nifedipine on Uteroplacental and Fetal Hemodynamics in Gestational Hypertension. Hypertens. pregnancy 2012, 31, 31–39, doi:10.3109/10641955.2010.525274.

[17] Alavifard, S.; Chase, R.; Janoudi, G.; Chaumont, A.; Lanes, A.; Walker, M.; Gaudet, L. First-Line Antihypertensive Treatment for Severe Hypertension in Pregnancy: A Systematic Review and Network Meta-Analysis. Pregnancy Hypertens. 2019, 18, 179–187, doi:10.1016/J.PREGHY.2019.09.019.

[18] Podymow, T.; August, P. Antihypertensive Drugs in Pregnancy. Semin. Nephrol. 2011, 31, 70–85, doi:10.1016/J.SEMNEPHROL.2010.10.007.

[19] Gupta, M.; Khalili, Y. Al Methyldopa. xPharm Compr. Pharmacol. Ref. 2023, 1–5, doi:10.1016/B978-008055232-3.62162-2.

[20] Cohen, J.S. Adverse Drug Effects, Compliance, and Initial Doses of Antihypertensive Drugs Recommended by the Joint National Committee vs the Physicians’ Desk Reference. Arch. Intern. Med. 2001, 161, 880–885, doi:10.1001/ARCHINTE.161.6.880.

[21] Taibanguay, N.; Chaiamnuay, S.; Asavatanabodee, P.; Narongroeknawin, P. Effect of Patient Education on Medication Adherence of Patients with Rheumatoid Arthritis: A Randomized Controlled Trial. Patient Prefer. Adherence 2019, 13, 119, doi:10.2147/PPA.S192008.